Skip to main content
Clinical Trials/JPRN-jRCT1061230097
JPRN-jRCT1061230097
Recruiting
未知

A study to verify the acute therapeutic effect of mepolizumab for eosinophilicpolyangiitis granulomatosis (EGPA) neuropathy(A Prospective Observational Study)

Takeshita Yukio0 sites20 target enrollmentFebruary 1, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Takeshita Yukio
Enrollment
20
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2024
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Takeshita Yukio

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients \=\<30 day after onset of EGPA neuropathy.
  • 2\) Patients who treated with steroid\-pulse therapy (3 days) during the acute phase of EGPA neuropathy and shown no complete remission in EGPA neuropathy.
  • 3\) Patients who meet the American Society of Rheumatology EGPA classification criteria or American College of Rheumatology/European League Against Rheumatism EGPA classification criteria.
  • 4\) Patients aged 20 years or older at the time of onset of EGPA neuropathy.
  • 5\) Regardless of gender.
  • 6\) Patients who gave informed consent to participate in the study by the patient or the legally acceptable
  • representative after receiving adequate explanation for their participation in the study.

Exclusion Criteria

  • 1\) Patients being treated with mepolizumab
  • 2\) Patients who received steroid\-pulse therapy (3 days) in the acute phase of EGPA neuropathy and had complete EGPA neuropaty resolution.
  • 3\) Life\-threatening patients
  • 4\) Patients who were judged inappropriate by principal investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials